HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
BTD
biotinidase
Chromosome 3 Β· 3p25.1
NCBI Gene: 686Ensembl: ENSG00000169814.18HGNC: HGNC:1122UniProt: A0A2R8Y5J9
67PubMed Papers
21Diseases
0Drugs
251Pathogenic Variants
RESEARCH IMPACT
Variant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
protein bindingGO:0005615extracellular exosomebiotinidase activitybiotinidase deficiencygenetic disordervitamin metabolic disorderoptic atrophy
✦AI Summary

Biotinidase (BTD) is a hydrolase enzyme that catalyzes the release of biotin from biocytin, the degradation product of biotin-dependent carboxylases. This biotin recycling function is essential for maintaining adequate biotin cofactor availability for multiple metabolic carboxylase enzymes. BTD is localized to extracellular spaces, the mitochondrial matrix, and extracellular exosomes, positioning it to facilitate biotin salvage in both intracellular and extracellular compartments. The enzyme displays hydrolase activity acting on carbon-nitrogen bonds in linear amides and interacts with other proteins as part of its functional mechanism. BTD deficiency is the primary disease association for this gene, resulting in biotinidase deficiency, a rare autosomal recessive disorder characterized by impaired biotin recycling. This deficiency leads to biotin depletion and subsequent dysfunction of biotin-dependent carboxylases, causing neurological complications, skin manifestations, and other metabolic abnormalities. Early diagnosis through newborn screening and biotin supplementation can prevent or ameliorate clinical symptoms, making BTD deficiency a treatable metabolic disorder. The gene's central role in biotin metabolism and its involvement in central nervous system development underscore the clinical importance of maintaining normal BTD enzyme activity for optimal neurological and metabolic health.

Sources cited
1
All statements about BTD function, localization, and biotinidase deficiency are based on the NCBI summary, UniProt annotations, and GO annotations provided in the prompt, not on the PubMed abstracts supplied, which focus on spinal muscular atrophy therapeutics, postoperative delirium, BTK inhibitors, and metagenomicsβ€”none of which discuss biotinidase.
PMID: No supporting abstracts provided
⚠Limited data available β€” This gene has 1 indexed publication. Summary and analysis may be incomplete.
Disease Associationsβ“˜21
biotinidase deficiencyOpen Targets
0.84Strong
genetic disorderOpen Targets
0.54Moderate
vitamin metabolic disorderOpen Targets
0.46Moderate
optic atrophyOpen Targets
0.37Weak
Leigh syndromeOpen Targets
0.19Weak
Global developmental delayOpen Targets
0.15Weak
Intellectual disabilityOpen Targets
0.14Weak
cryptorchidismOpen Targets
0.11Weak
Generalized hypotoniaOpen Targets
0.11Weak
MacrocephalyOpen Targets
0.11Weak
diabetes mellitusOpen Targets
0.11Weak
thyroid cancerOpen Targets
0.08Suggestive
metabolic syndromeOpen Targets
0.06Suggestive
hyperinsulinemic hypoglycemia, familial, 4Open Targets
0.05Suggestive
disorder of glycogen metabolismOpen Targets
0.05Suggestive
Isolated 3-methylcrotonyl-CoA carboxylase deficiencyOpen Targets
0.05Suggestive
breast cancerOpen Targets
0.04Suggestive
HyperphenylalaninemiaOpen Targets
0.04Suggestive
Young adult-onset ParkinsonismOpen Targets
0.04Suggestive
hypermanganesemia with dystonia 2Open Targets
0.04Suggestive
Biotinidase deficiencyUniProt
Pathogenic Variants251
NM_001370658.1(BTD):c.565C>T (p.Arg189Cys)Pathogenic
Biotinidase deficiency|not provided|Inborn genetic diseases
β˜…β˜…β˜†β˜†2026β†’ Residue 189
NM_001370658.1(BTD):c.410G>A (p.Arg137His)Pathogenic
Biotinidase deficiency|not provided|Inborn genetic diseases
β˜…β˜…β˜†β˜†2026β†’ Residue 137
NM_001370658.1(BTD):c.*159G>APathogenic
Biotinidase deficiency|BTD-related disorder
β˜…β˜…β˜†β˜†2026
NM_001370658.1(BTD):c.1301A>G (p.Tyr434Cys)Pathogenic
Biotinidase deficiency|not provided|BTD-related disorder|Possible mitochondrial disorder - nuclear genes
β˜…β˜…β˜†β˜†2026β†’ Residue 434
NM_001370658.1(BTD):c.468G>T (p.Lys156Asn)Pathogenic
Biotinidase deficiency|not provided|Inborn genetic diseases
β˜…β˜…β˜†β˜†2026β†’ Residue 156
NM_001370658.1(BTD):c.583C>T (p.Leu195Phe)Pathogenic
Biotinidase deficiency
β˜…β˜…β˜†β˜†2026β†’ Residue 195
NM_001370658.1(BTD):c.419G>A (p.Cys140Tyr)Likely pathogenic
Biotinidase deficiency
β˜…β˜…β˜†β˜†2026β†’ Residue 140
NM_001370658.1(BTD):c.38_44delinsTCC (p.Cys13fs)Pathogenic
Biotinidase deficiency|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 13
NM_001370658.1(BTD):c.1308A>C (p.Gln436His)Pathogenic
Biotinidase deficiency|not provided|Inborn genetic diseases|BTD-related disorder|Intellectual disability
β˜…β˜…β˜†β˜†2026β†’ Residue 436
NM_001370658.1(BTD):c.1552C>A (p.Arg518Ser)Pathogenic
Biotinidase deficiency|Inborn genetic diseases
β˜…β˜…β˜†β˜†2026β†’ Residue 518
NM_001370658.1(BTD):c.1429C>T (p.Pro477Ser)Pathogenic
Biotinidase deficiency|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 477
NM_001370658.1(BTD):c.1553G>A (p.Arg518His)Pathogenic
Biotinidase deficiency|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 518
NM_001370658.1(BTD):c.641C>T (p.Thr214Ile)Pathogenic
Biotinidase deficiency
β˜…β˜…β˜†β˜†2026β†’ Residue 214
NM_001370658.1(BTD):c.40G>A (p.Gly14Ser)Pathogenic
Biotinidase deficiency|BTD-related disorder
β˜…β˜…β˜†β˜†2026β†’ Residue 14
NM_001370658.1(BTD):c.1167_1181delinsTTCCAATGGCC (p.Trp389fs)Pathogenic
Biotinidase deficiency|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 389
NM_001370658.1(BTD):c.527del (p.Thr176fs)Pathogenic
Biotinidase deficiency
β˜…β˜…β˜†β˜†2026β†’ Residue 176
NM_001370658.1(BTD):c.1552C>T (p.Arg518Cys)Pathogenic
Biotinidase deficiency|not provided|Inborn genetic diseases|BTD-related disorder
β˜…β˜…β˜†β˜†2026β†’ Residue 518
NM_001370658.1(BTD):c.566G>A (p.Arg189His)Pathogenic
Biotinidase deficiency|not provided|BTD-related disorder
β˜…β˜…β˜†β˜†2026β†’ Residue 189
NM_001370658.1(BTD):c.695A>G (p.Asp232Gly)Pathogenic
Biotinidase deficiency|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 232
NM_001370658.1(BTD):c.400-2A>GLikely pathogenic
not provided|Biotinidase deficiency
β˜…β˜…β˜†β˜†2026
View on ClinVar β†—
Related Genes
ZIC5Shared pathway100%ZIC4Shared pathway100%SNTG2Shared pathway100%JRKLShared pathway100%NPAS1Shared pathway100%NHLH2Shared pathway100%
Tissue Expression6 tissues
Liver
100%
Ovary
55%
Heart
40%
Bone Marrow
30%
Brain
30%
Lung
27%
Gene Interaction Network
Click a node to explore
BTDZIC5ZIC4SNTG2JRKLNPAS1NHLH2
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted Β· UniProt P43251
View on AlphaFold β†—
Constraintβ“˜
LOEUFβ“˜
1.22LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.79 [0.53–1.22]
RankingsWhere BTD stands among ~20K protein-coding genes
  • #6,966of 20,598
    Most Researched67
  • #255of 5,498
    Most Pathogenic Variants251 Β· top 5%
  • #12,840of 17,882
    Most Constrained (LOEUF)1.22
Genes detectedBTD
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
PMID: 29091570
N Engl J Med Β· 2017
1.00
2
Challenges and opportunities in spinal muscular atrophy therapeutics.
PMID: 38267192
Lancet Neurol Β· 2024
0.90
3
Perioperative Factors Associated With Postoperative Delirium in Patients Undergoing Noncardiac Surgery: An Individual Patient Data Meta-Analysis.
PMID: 37819663
JAMA Netw Open Β· 2023
0.80
4
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
PMID: 29443664
N Engl J Med Β· 2018
0.70
5
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study.
PMID: 38330285
Neurology Β· 2024
0.60